We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Novel Brain-Stimulation Device Treats Migraines

By HospiMedica International staff writers
Posted on 15 Jan 2014
A portable migraine-fighting device uses trans-cranial magnetic stimulation (TMS) technology to relieve pain in most extreme migraine cases.

The SpringTMS Total Migraine System is designed to treat migraines that are preceded by a sensory disturbance, using a millisecond-long magnetic pulse to stimulate the brain, thus easing the pain. More...
The prescription device is used after the onset of pain associated with migraine headaches preceded by an aura. Using both hands to hold the device against the back of the head, the user presses a button to release a pulse of magnetic energy to stimulate the occipital cortex in the brain. The magnetic field induces very mild electrical currents in the brain tissue to excite and depolarize neurons, interrupting abnormal electrical activity.

The portable, easy-to-use, device automatically records treatment history and provides a convenient headache diary that can be filled out after each treatment, or at any time after the migraine subsides. In a pivotal trial on 201 patients, nearly 38% of migraine sufferers who used the device were pain-free two hours after onset, compared to about 17% in the control group, and nearly 34% of those in the treatment arm stayed that way after 24 hours, compared to the 10% rate of the control segment.

The SpringTMS Total Migraine System is a product of eNeura Therapeutics (Sunnyvale, CA, USA), and has been approved by the US Food and Drug Administration (FDA). The device must not be used if the patient has implanted metal prostheses in the head, neck, or upper body that are attracted by a magnet, or if they have an active implanted medical device such as a pacemaker or deep brain stimulator (DBS). It should also not be used in patients with suspected or diagnosed epilepsy or a personal or family history of seizures.

Migraine headaches are characterized by intense pulsing or throbbing pain in one area of the head accompanied by nausea and/or vomiting and sensitivity to light and sound. A migraine can last anywhere between 4 and 72 hours when untreated. The debilitating headaches affect about 10% of people worldwide, and are three times more common in women than in men. About one third of people with migraines experience an aura.

Related Links:
eNeura Therapeutics


Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Bipolar Coagulation Generator
Aesculap
Endoscopy Display
E190
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The AI-based approach identifies lipid regions matched well with histopathology results (Photo courtesy of Hyeong Soo Nam/KAIST)

AI-Based OCT Image Analysis Identifies High-Risk Plaques in Coronary Arteries

Lipid-rich plaques inside coronary arteries are strongly associated with heart attacks and other major cardiac events. While optical coherence tomography (OCT) provides detailed images of vessel structure... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.